The humanized mouse models market is projected to grow at a CAGR of 9.9% and humanized rat models market is projected to grow at a CAGR of 8.4%. The humanized mouse models market is projected to reach USD 128.9 million by 2022 from USD 80.3 million in 2017, at a CAGR of 9.9% during the forecast period. The humanized rat models market is expected to reach USD 8.9 million by 2022 from USD 5.9 million in 2017, at a CAGR of 8.4% during the forecast period. The major influencing factors driving the growth of this market are increasing number of research activities involving humanized models, growing demand for personalized medicine, increasing number of R&D activities in pharmaceutical and biotechnology companies, and continuous support in the form of investments and grants from the government and private sectors.
The cell-based humanized mouse models segment is expected to register the highest growth rate during the forecast period. On the basis of type, the humanized mouse models are segmented into genetic and cell-based humanized mouse models.The cell-based humanized mouse models segment is expected to grow at the highest CAGR during the study period (2017–2022).
The high growth of this segment can be attributed to the growing applications of cell-based humanized mouse models. Furthermore, the cell-based humanized mouse models are categorized into CD34, PBMC, and BLT humanized mouse models.The CD34 humanized mouse models segment is estimated to account for the largest share and register the highest growth rate during the forecast period.
The major factors contributing the large share and high growth rate of this segment include usage of CD34 mouse models in in-vivo platforms for analyzing the safety and effectiveness of potential new drugs that can modulate the immune system. Thus, the growing application areas of CD34 models are likely to spur the market during the forecast period.
The Contract Research Organizations (CROs) segment is expected to be the fastest growing end-user segment. Humanized mouse models market is categorized into three end-user segments, namely, pharmaceutical & biotechnology companies, contract research organizations (CROs), and academic & research institutions.The contract research organizations (CROs) segment of the market is estimated to grow at the highest CAGR during the forecast period.
This can be attributed to the increasing number of pharmaceutical companies outsourcing their preclinical studies to contract research organizations (CROs).
In 2017, North America dominated the humanized mouse models market and Asia Pacific is projected to grow at the highest CAGR during the forecast period. The humanized mouse models market is divided into four major regions— North America, Europe, Asia Pacific, and the Rest of the World.North America accounted for the largest share of the humanized mouse models market.
The major factors contributing to the large share of this segment include preclinical activities by CROs and pharmaceutical R&D, increasing monoclonal antibody production, growing biomedical research in the US along with government support for the development of protein drugs, and growing stem cell research in Canada.
Asia Pacific is expected to register the highest CAGR during the forecast period.The major factors driving the growth of this regional segment include international alliances for R&D activities in China, initiatives to reduce approval time for drugs, growing biomedical and medical research in Japan.
Furthermore, the growth of the biomedical industry in India, increase in animal research in Malaysia, and ongoing biomedical research activities in Australia are also driving the growth of the market in Asia Pacific.
Break of primary participants was as mentioned below: • By Company Type – Tier 1: 31%, Tier 2: 40%, and Tier 3: 29% • By Designation – C-level: 37%, Director Level: 40%, Others: 23% • By Region – North America: 34%, Europe: 28%, Asia Pacific: 26%, RoW: 12%
The major market players in the humanized mouse models market include The Jackson Laboratory (US), Taconic Biosciences, Inc. (US), Horizon Discovery Group plc (UK), genOway, S.A. (France), Crown Bioscience, Inc. (US), and Champions Oncology, Inc. (US). The major players in the humanized rat models market include Horizon Discovery Group plc (UK), Hera BioLabs (US), and Yecuris Corporation (US).
Research Coverage: The report analyzes the market and aims at estimating the market size and the future growth potential of this market based on various segments such as type, application, end user, and region. The report also includes competitive landscape of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned strategies.
This report provides insights on the following pointers: • Market Penetration: Comprehensive information on products and services offered by the top players in the global humanized mouse and rat models market • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the humanized mouse and rat models market • Market Development: Comprehensive information about the lucrative emerging markets by type, application, end user, and region • Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global humanized mouse and rat models market • Competitive Assessment: In-depth assessment of market shares, growth strategies, and products of leading players in the global market
Our reports have been used by over 10K customers, including:
The quantitative structure-activity relationship (QSAR) market is expected to reach US$ 1,888.5 million by 2027 from US$ 1,388.1 million in 2019; it is estimated to grow at a CAGR of 4.0% during 2020–2027. The market growth is mainly attributed to the increasing adoption rate of modeling tools in drug discovery and rising investments for drug...
Certain factors that are driving the market growth include rising healthcare expenditure, growing burden of chronic diseases and advances in drug discovery and development. The burden of chronic diseases is increasing worldwide. According to WHO, chronic diseases have always been a massive global challenge, and they account for approximately...
The global in vivo toxicology market size is projected to reach USD 6.6 billion by 2025 from USD 5.0 billion in 2020, at a CAGR of 5.5% during the forecast period. Market growth is driven largely by the increasing pharmaceutical R&D activities, innovations in animal models, the development of exclusive in vivo toxicology tests, and the increasing...
The cell-based assays market is projected to reach USD 22.0 billion by 2025 from USD 14.9 billion in 2020, at a CAGR of 8.1% during the forecast period. The growing preference for cell-based assays in drug discovery, increasing funding for cell-based research, and growth in the number of drug discovery activities are the key factors supporting...
The global high-throughput screening market size is projected to reach USD 26.4 billion by 2025 from USD 15.3 billion in 2020, at a CAGR of 11.5% during the forecast period. The growth in this market is primarily attributed to increasing R&D spending by pharmaceutical & biotechnology companies, technological advancements in high-throughput...
The Global Electronic Clinical Outcome Assessment Solution Market (eCOA) size is expected to reach $2.4 billion by 2026, rising at a market growth of 19% CAGR during the forecast period. Electronic clinical outcome assessment (eCOA) refers to a system that is capable of measuring mental state, patient symptom, and the prognosis of a disease....
An organ-on-a-chip is a microfluidic cell culture device that contains continuously perfused chambers. This chip develops a narrow channel for the blood and airflow in organs, such as the lung, gut, liver, heart, and other organs. Such devices produce multiple levels of tissue and organ functionalities, which are not feasible using conventional...
The research antibodies and reagents market is projected to reach USD 14.1 billion by 2025 from USD 10.1 billion in 2020, at a CAGR of 6.7% during the forecast period. The research antibodies and reagents market has evolved owing to factors such as growth in proteomics and genomics research, rising demand for high-quality antibodies for research...
Drug Development
United States
Europe
APAC
Cancer Incidence
Health Expenditure
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.
